| Hazard Information | Back Directory | [Uses]
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes[1]. | [in vivo]
Insulin efsitora alfa (3, 10 and 30 nmol/kg; s.c.; single dose) significantly reduces blood glucose in diabetes rats treated with Streptozotocin (HY-13753)[2]. | [References]
[1] Heise T, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023 Apr;25(4):1080-1090. DOI:10.1111/dom.14956
[2] Moyers JS, et al. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. J Pharmacol Exp Ther. 2022 Sep;382(3):346-355. DOI:10.1124/jpet.122.001105 |
|
|